Repotrectinib US FDA Label

  • Compound: (3R,11S)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
  • Description: Repotrectinib is an azamacrocycle with formula C18H18FN5O2. It is a tyrosine kinase inhibitor (highly potent against ROS1, TRKA-C, and ALK) used for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer. It has a role as an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor and an antineoplastic agent. It is a member of monofluorobenzenes, a pyrazolopyrimidine, a cyclic ether, a secondary carboxamide and an azamacrocycle.

Identifiers (5)

  • International Nonproprietary Name: REPOTRECTINIB [INN] (Source: PubChem)
  • KEGG Compound ID: C73438 (Source: PubChem)
  • KEGG Drug ID: D11454 (Source: PubChem)
  • USFDA Precision ID: UNII-08O3FQ4UNP (Source: PubChem)
  • US Adopted Name: Repotrectinib [USAN] (Source: PubChem)

    • Sources: PubChem (5)